Table 4.
The HBV therapeutic development landscape as of 2019.
| Target/strategy | Preclinical | Human Phase trials | |
|---|---|---|---|
| DDA | Entry | Myrcludex B (MyrB) | |
| DNA pol | Tenofovir exalidex, CMX-157, hexadecyloxypropyl-tenofovir (Contravir Pharmaceuticals) ─ TAF (GS) ─ Clevudine (Korea) | ||
| siRNA/antisense | Ben BBHB 331 ─ DCR HBs ─ RG6004 ─ LunarHBV Janssen | ARO HBV RNAi ─ Aln Vir HBV ─ ARB 467 RNAi ─ IONIS-HBV-LRx IONIS-HBVRx | |
| sAg | BSBI edi2 ─ BSBI 259 sAg ─ TTP sAg | REP 2139 ─ REP 2165* | |
| Capsid | Benza capsid ─ CpAMS capsid | AB 423 capsid ─ ABI H2158 ─ ABI H0731 ─ RG7907 ─ AB 503 ─ QL 007 ─ RG7048 ─ GLS-4 HEC ─ ABI 7031 ─ J&J 6379 | |
| RNA destabilizers | EBT 106 ─ Roche DHQ ─ AB 452 | ||
| cccDNA | CRISPCAS (intel)ia ─ CRIPR CoCrystal ─ BSBI (Jt Guo) | ALN-HBV ─ ARB-1467 ─ ARC RNAi | |
| Host | Non immunomodulators | EYP001 FXR Enyo ─ GS 5801 [inhibitor of histone demethylase (lysine demethylase 5 (KDM5)] | EYP001 ─ Lonafarnib* EI |
| Innate Immune modulators | GS 9688 (TLR 8 agonist) | SB 9200 (RIG 1+, di-nuc) ─ Poly IC (interferon pathway) ─ HBV inf den cells (Ag presentation) ─ Inarigivir (RIG I/STING) ─ GS-9620 (vesatolimod - TLR 7 agonist) ─ Nivolumab (anti-PD-1) | |
| Adaptive immune modulators/vaccines | Imm TAV TCR IC ─ Tomega Vax ─ MVA-VIP GV | CVIHBV002 ─ ABX203 ─ Ino 1800 ─ DV601 ─ HB110 Ichor ─ INO 1800 ─ TG 1050 ─ IFN + IL2 + vaccine |
AB, ARB: Arbutus; ABI, Aln, Alnylam; Alt, Altimmune; Apg, Ascentage; BSBI, Blumberg; Ben, Benitech; DCR, Dicerna; EBT, Excision; EI, Eiger, EY, Enyo, GS, Gilead; INO, Innovio; Rep, Replicor; GV, Genvax; GSK, Glaxo; IC, Immunocore; RG, Roche; SB, Springbank; TG, Transgene.